This is a summary of the European public assessment report (EPAR) for Celsentri. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Celsentri. For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable
Therapeutic Area (MeSH)
ATC Code
J05AX09
ATC Item
maraviroc
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| maraviroc | N/A | 马拉韦罗 |
EMA Name
Celsentri
Medicine Name
Celsentri
Aliases
N/ANo risk management plan link.
